Neutralizing monoclonal antibodies for treatment of COVID-19

Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical trials. With the US Food and Drug Administration recently granting emergency use authorizations for neutralizing mAbs in non-...

Descripción completa

Detalles Bibliográficos
Autores principales: Taylor, Peter C., Adams, Andrew C., Hufford, Matthew M., de la Torre, Inmaculada, Winthrop, Kevin, Gottlieb, Robert L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8054133/
https://www.ncbi.nlm.nih.gov/pubmed/33875867
http://dx.doi.org/10.1038/s41577-021-00542-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8054133/
https://www.ncbi.nlm.nih.gov/pubmed/33875867
http://dx.doi.org/10.1038/s41577-021-00542-x

Ejemplares similares